Auris Medical Hld

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

The stock price of Auris Medical Holding Ltd. (NASDAQ: EARS) increased by over 4% pre-market.

EARS Stock Price Increased Over 4% Pre-Market: Why It Happened

Hamilton, Bermuda, March 31, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today provided a business update and announced second half and full year 2020 financial results.

Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results

The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by 52.05% yesterday. This is why it happened.

EARS Stock Price Increased 52.05%: Why It Happened

Auris Medical (EARS) stock is heading higher on Tuesday with heavy trading of the shares despite a lack of news concerning the company. The post EARS Stock: 7 Things for Auris Medical Investors to Know as Shares Continue to Soar appeared first on InvestorPlace.

EARS Stock: 7 Things for Auris Medical Investors to Know as Shares Continue to Soar

The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) has increased by over 30% pre-market. This is why it happened.

EARS Stock Price Increases Over 30% Pre-Market: Why It Happened

Auris Medical Holding Ltd. (NASDAQ: EARS) shares traded on increased volume during Friday's trading session.

Auris Medical Trading Higher On Increased Volume: Technicals To Watch

Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced with its affiliate Altamira Medica AG the initiation of a clinical investigation of AM-301 in allergic rhinitis.

Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.mysequire.com/ .

Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference

Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 2,000,000 common shares, par value CHF 0.01 per share, at an offering price of $4.00 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The gross proceeds of the offering will be approximately $8,000,000 before deducting fees and other estimated offering expenses. The Company intends to use the net proceeds for working capital and general corporate purposes. The closing of the registered direct offering is expected to take place on or about December 4, 2020, subject to the satisfaction of customary closing conditions. 

Auris Medical Holding Ltd. Prices $8,000,000 Common Shares Offering Priced At-the-Market

Auris Medical soared as high as 480% on Tuesday after it announced lab-test results that show its nasal spray could protect against the coronavirus. Shares of the Bermuda-based clinical stage company are now trading at over $5 per share, after closing at just $1.1 on Monday. Auris tested its nasal spray, AM-301, on human nasal cells reconstituted in a lab. Auris found that cultures treated with AM-301 right before inoculation with the coronavirus saw effective protection against the virus.

Auris Medical skyrockets 480% after announcing lab-test results that show its nasal spray could protect against Covid-19 (EARS)

EARS stock typically flies under the radar, but today it is getting a boost thanks to trial data from a Covid-19 treatment. The post EARS Stock: Why Auris Medical Shares Are Soaring 450% appeared first on InvestorPlace.

EARS Stock: Why Auris Medical Shares Are Soaring 450%

Auris Medical (NASDAQ: EARS) shares are ripping higher on Tuesday after the company reported positive efficacy data for its AM-301 in protecting against Sars COVID-19 infections. Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company.

Why Auris Medical's Stock Is Trading Higher By 445% Today

Hamilton, Bermuda, December 1, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced positive efficacy data from testing AM-301 in vitro. AM-301 is a drug-free nasal spray being developed by the Company's affiliate Altamira Medica for protection against airborne pathogens and allergens.

Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the launch of a dedicated website for its affiliate Altamira Medica Ltd. The website, www.altamiramedica.com , offers quick and easy access to information about the Company's development of AM-301, a drug-free nasal spray intended for self-protection against risks from exposure to airborne viruses and allergens.   

Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

Auris Medical (EARS) news for Tuesday includes the start of enrollment for the second part of a Phase 2 study to treat acute vertigo. The post Auris Medical News: Why EARS Stock Is Soaring 24% Today appeared first on InvestorPlace.

Auris Medical News: Why EARS Stock Is Soaring 24% Today

Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the first patient has been randomized in Part B of its “TRAVERS” Phase 2 trial of AM-125 (intranasal betahistine) in acute vertigo. This follows the positive read-out from the interim analysis on Part A of the study in early September 2020, the completion of enrollment into the oral treatment group, and the receipt of regulatory clearance for Part B in the first three of the participating study countries.

Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo

Auris Medical Holding Ltd. (EARS) CEO Thomas Meyer on Q2 2020 Results - Earnings Call Transcript

Hamilton, Bermuda, September 17, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today provided a business update and announced financial results for the first half of the 2020 financial year ended June 30, 2020.

Auris Medical Provides Business Update and Reports First Half 2020 Financial Results

Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it will provide a business update and report its financial results for the first half 2020 on Thursday, September 17, 2020. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:30 am Eastern Time (2:30 pm Central European Time).

Auris Medical to Report First Half 2020 Financial Results and Provide Business Update on Thursday, September 17, 2020

Hamilton, Bermuda, September 8, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the launch of the development of AM-301, a drug-free nasal spray for protection against airborne pathogens and allergens, based on positive data obtained in a SARS-CoV-2 assay. In order to expedite the development process, Auris Medical set up a new subsidiary, Altamira Medica Ltd. (“Altamira”), based in Zug, Switzerland, and has already obtained funding through a CHF 1.5 m convertible loan agreement.

Auris Medical Launches Development of Drug-Free Nasal Spray for Protection against Airborne Pathogens and Allergens

Hamilton, Bermuda, September 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive top-line data from the interim analysis of its Phase 2 “TRAVERS” trial with intranasal betahistine in vertigo (AM-125).

Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo

Hamilton, Bermuda, August 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it has regained compliance with the Nasdaq listing requirements. On August 20, 2020, the Company received a letter from Nasdaq stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed.

Auris Medical Regains Listing Compliance with NASDAQ Minimum Bid Requirement

Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the completion of patient enrollment into Part A of its Phase 2 “TRAVERS” trial with intranasal betahistine in vertigo (AM-125). The Company expects to release interim results from TRAVERS and commence Part B of the trial in the coming weeks.

Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo

Hamilton, Bermuda, May 26, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive top-line data from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and provided an update on the enrollment into its Phase 2 trial with AM-125 in vertigo.

Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study

       Hamilton, Bermuda, April 16, 2020 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today provided a business update and announced financial results for the second half and full year ended December 31, 2019.

News for Auris Medical Hld Stock (EARS)